LifeMD (LFMDP) EBIT (2012 - 2025)

LifeMD has reported EBIT for 14 years, with the latest figure at -$6.2 million in Q4 2025.

• For the quarter ending Q4 2025, EBIT fell 4.26% year-over-year to -$6.2 million; the trailing twelve-month figure through Dec 2025 stood at -$5.6 million (up 75.13% YoY), and the FY2025 full-year result was -$7.7 million, up 62.41% from the prior year.
• EBIT for Q4 2025 stood at -$6.2 million, down from -$2.0 million in the prior quarter.
• The five-year high for EBIT was $2.2 million in Q1 2025, with the low at -$16.1 million in Q2 2021.
• Historically, EBIT has averaged -$7.0 million across 5 years, with a median of -$6.2 million in 2024.
• Annual changes were most pronounced in 2021 — EBIT tumbled 584.76% — and 2025, when it soared 134.94%.
• LifeMD's EBIT stood at -$13.7 million in 2021, then grew by 24.1% to -$10.4 million in 2022, then soared by 79.06% to -$2.2 million in 2023, then tumbled by 174.87% to -$6.0 million in 2024, then declined by 4.26% to -$6.2 million in 2025.
• The last three EBIT figures came in at -$6.2 million (Q4 2025), -$2.0 million (Q3 2025), and $455210.0 (Q2 2025), per Business Quant data.